X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with TKIs.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: LP-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Reprocell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2023
Details:
LP-300, or tavocept (Disodium 2,2’-dithio-bis-ethane sulfonate), is a small molecule entity with cysteine modifying activity on select proteins, works to modulate multiple cellular pathways simultaneously and is potential first-in-class combination agent indicated in NSCLC.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tavocept
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
